|
Levetiracetam in sodium chloride injection is an antiepileptic drug indicated for adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy, myoclonic seizures in adults with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy."
The said drug is a generic therapeutic equivalent of the Reference Listed Drug (RLD) from HQ Specialty Pharma Corp.
This is the second Ready-To-Use Infusion bag (RTU Bags) ANDA drug product approved for Caplin Steriles, with a further 6 products under review with FDA for RTU Bags segment.
According to IQVIATM (IMS Health), Levetiracetam in Sodium Chloride Injection had US sales of approximately $19 million for the 12-month period ending November 2024.
Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms.
The company’s consolidated net profit grew 14.04% to Rs 130.80 crore on 17.81% increase in revenue from operations to Rs 483.10 crore in Q2 FY25 over Q2 FY24.
The scrip slipped 1.27% to Rs 2,241 on the BSE.
|